# Organon & Co.: overview

OGN · NYSE · CIK 1821825 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ogn.md) · [Financials](/companies/ogn/financials.md) · [Filings](/companies/ogn/filings.md) · [Insiders](/companies/ogn/insiders.md)

Latest reported revenue: [$1.57bn](/filings/0001821825-26-000004.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 30, 2026 (XBRL us-gaap:Revenues, accession 0001821825-26-000004).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,592 d](/filings/0001628280-26-011125.md) | [1,513](/filings/0001628280-26-029532.md) | [1,594](/filings/0001628280-26-051230.md) | [1,602](/filings/0001821825-26-000004.md) | [1,507 d](/filings/0001628280-26-011125.md) | [1,460](/filings/0001628280-26-029532.md) | [1,558](/filings/0001628280-26-051230.md) | [1,574](/filings/0001821825-26-000004.md) |
| Gross margin | % | [56.3% d](/filings/0001628280-26-011125.md) | [55.6%](/filings/0001628280-26-029532.md) | [54.8%](/filings/0001628280-26-051230.md) | [53.5%](/filings/0001821825-26-000004.md) | [49.2% d](/filings/0001628280-26-011125.md) | [53.6%](/filings/0001628280-26-029532.md) | [54.4%](/filings/0001628280-26-051230.md) | [55.2%](/filings/0001821825-26-000004.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [6.8% d](/filings/0001628280-26-011125.md) | [5.8%](/filings/0001628280-26-029532.md) | [9.1%](/filings/0001628280-26-051230.md) | [10.0%](/filings/0001821825-26-000004.md) | [(13.6%) d](/filings/0001628280-26-011125.md) | [10.0%](/filings/0001628280-26-029532.md) | [6.9%](/filings/0001628280-26-051230.md) | [10.4%](/filings/0001821825-26-000004.md) |
| Diluted EPS | $ per share | not reported | [0.33](/filings/0001628280-26-029532.md) | [0.56](/filings/0001628280-26-051230.md) | [0.61](/filings/0001821825-26-000004.md) | not reported | [0.55](/filings/0001628280-26-029532.md) | [0.40](/filings/0001628280-26-051230.md) | [0.60](/filings/0001821825-26-000004.md) |
| Free cash flow | $m | [335 d](/filings/0001628280-26-011125.md) | [43.0](/filings/0001628280-26-029532.md) | [181 d](/filings/0001628280-26-051230.md) | [218 d](/filings/0001821825-26-000004.md) | [96.0 d](/filings/0001628280-26-011125.md) | [188](/filings/0001628280-26-029532.md) | [65.0 d](/filings/0001628280-26-051230.md) | [326 d](/filings/0001821825-26-000004.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6,304](/filings/0001628280-24-006733.md) | [6,174](/filings/0001104659-25-108693.md) | [6,263](/filings/0001628280-26-011125.md) | [6,403](/filings/0001628280-26-011125.md) | [6,216](/filings/0001628280-26-011125.md) |
| Gross margin | % | not reported | [62.8%](/filings/0001104659-25-108693.md) | [59.8%](/filings/0001628280-26-011125.md) | [58.0%](/filings/0001628280-26-011125.md) | [53.3%](/filings/0001628280-26-011125.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [21.4%](/filings/0001628280-24-006733.md) | [14.9%](/filings/0001104659-25-108693.md) | [16.3%](/filings/0001628280-26-011125.md) | [13.5%](/filings/0001628280-26-011125.md) | [3.0%](/filings/0001628280-26-011125.md) |
| Diluted EPS | $ per share | [5.31](/filings/0001628280-24-006733.md) | [3.59](/filings/0001104659-25-108693.md) | [3.99](/filings/0001628280-26-011125.md) | [3.33](/filings/0001628280-26-011125.md) | [0.72](/filings/0001628280-26-011125.md) |
| Free cash flow | $m | [1,968](/filings/0001628280-24-006733.md) | [662](/filings/0001104659-25-108693.md) | [548](/filings/0001628280-26-011125.md) | [764](/filings/0001628280-26-011125.md) | [538](/filings/0001628280-26-011125.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ogn/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $434.0m | 32,056,866 |  | Added +339,838 |
| [Pentwater Capital Management LP](/funds/1425851.md) | 2026-06-30 | $245.1m | 18,100,000 |  | New +18,100,000 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $204.9m | 15,132,118 |  | Reduced −6,713,918 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $161.3m | 11,909,865 |  | Added +172,847 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $130.8m | 9,659,371 |  | Reduced −297,403 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $70.4m | 5,199,002 |  | Added +3,593,677 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $65.8m | 4,856,529 |  | Added +1,384,950 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $65.2m | 4,815,610 |  | Added +56,273 |
| [Man Group plc](/funds/1637460.md) | 2026-06-30 | $56.6m | 4,180,500 |  | New +4,180,500 |
| [AQR Arbitrage LLC](/funds/1167456.md) | 2026-06-30 | $52.4m | 3,880,354 |  | New +3,880,354 |

## Recent filings

[All 456 filings](/companies/ogn/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-30 | 08:17 ET | [8-K](/filings/0001104659-26-120423.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-120423 |
| 2026-10-30 | 08:03 ET | [10-Q](/filings/0001821825-26-000004.md) | Quarterly report, period 2026-09-30 | 0001821825-26-000004 |
| 2026-07-31 | 08:23 ET | [8-K](/filings/0001104659-26-089008.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-089008 |
| 2026-07-31 | 08:06 ET | [10-Q](/filings/0001628280-26-051230.md) | Quarterly report, period 2026-06-30 | 0001628280-26-051230 |
| 2026-07-23 | 17:13 ET | [8-K](/filings/0001193125-26-314587.md) | 5.07 Shareholder vote results | 0001193125-26-314587 |
| 2026-07-17 | 16:01 ET | [8-K](/filings/0001193125-26-307767.md) | 8.01 Other events | 0001193125-26-307767 |
| 2026-06-11 | 16:15 ET | [8-K](/filings/0001104659-26-072953.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-072953 |
| 2026-05-04 | 08:46 ET | [10-Q](/filings/0001628280-26-029532.md) | Quarterly report, period 2026-03-31 | 0001628280-26-029532 |
| 2026-04-30 | 07:48 ET | [8-K](/filings/0001104659-26-052165.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-052165 |
| 2026-04-27 | 06:06 ET | [8-K](/filings/0001193125-26-178718.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-178718 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-011125.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures. [See the target](/leagues/2026q3/targets/670da033-d3fb-4318-bc7e-733bfeeea89c)

## About the filer

- CIK: 1821825
- Tickers: OGN
- Exchange: NYSE
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 31, 2026, 03:06 ET. No prices; not investment advice.